[go: up one dir, main page]

AR062658A1 - COMBINATION THERAPIES FOR REUMATOID ARTHRITIS - Google Patents

COMBINATION THERAPIES FOR REUMATOID ARTHRITIS

Info

Publication number
AR062658A1
AR062658A1 ARP070103915A ARP070103915A AR062658A1 AR 062658 A1 AR062658 A1 AR 062658A1 AR P070103915 A ARP070103915 A AR P070103915A AR P070103915 A ARP070103915 A AR P070103915A AR 062658 A1 AR062658 A1 AR 062658A1
Authority
AR
Argentina
Prior art keywords
pharmaceutically acceptable
acceptable salt
arthritis
combination therapies
human
Prior art date
Application number
ARP070103915A
Other languages
Spanish (es)
Inventor
Paul Steven Changelian
Samuel Hyman Zwillich
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR062658A1 publication Critical patent/AR062658A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Terapias farmacéuticas de combinacion para el tratamiento o prevencion de artritis, tales como artritis reumatoide, en un ser humano, que comprende un inhibidor de la Quinasa Janus o una sal farmacéuticamente aceptable del mismo y al menos un agente anti-artrítico o una sal farmacéuticamente aceptable del mismo. Métodos para tratar o prevenir la artritis, tal como artritis reumatoide, en un ser humano, que comprende la coadministracion a un ser humano de un inhibidor de la Quinasa Janus o una sal farmacéuticamente aceptable del mismo y al menos una agente anti-artrítico o una sal farmacéuticamente aceptable del mismo.Combination pharmaceutical therapies for the treatment or prevention of arthritis, such as rheumatoid arthritis, in a human being, comprising a Janus Kinase inhibitor or a pharmaceutically acceptable salt thereof and at least one anti-arthritic agent or a pharmaceutically acceptable salt. of the same. Methods for treating or preventing arthritis, such as rheumatoid arthritis, in a human being, comprising co-administration to a human being of a Janus Kinase inhibitor or a pharmaceutically acceptable salt thereof and at least one anti-arthritic agent or a pharmaceutically acceptable salt thereof.

ARP070103915A 2006-09-05 2007-09-05 COMBINATION THERAPIES FOR REUMATOID ARTHRITIS AR062658A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84270406P 2006-09-05 2006-09-05

Publications (1)

Publication Number Publication Date
AR062658A1 true AR062658A1 (en) 2008-11-26

Family

ID=39047038

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103915A AR062658A1 (en) 2006-09-05 2007-09-05 COMBINATION THERAPIES FOR REUMATOID ARTHRITIS

Country Status (4)

Country Link
JP (1) JP2008069149A (en)
AR (1) AR062658A1 (en)
TW (1) TW200823216A (en)
WO (1) WO2008029237A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010239396B2 (en) * 2009-04-20 2016-06-23 Auspex Pharmaceuticals, Llc Piperidine inhibitors of Janus Kinase 3
TWI466885B (en) 2009-07-31 2015-01-01 Japan Tobacco Inc Nitrogen-containing spiro compound and its medical use
AR079984A1 (en) 2010-01-12 2012-03-07 Hoffmann La Roche TRICYCLIC HETEROCICLIC COMPOUNDS, COMPOSITIONS AND ITS USE IN THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF JAK1
WO2011097087A1 (en) * 2010-02-05 2011-08-11 Pfizer Inc. Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors
CN102875555A (en) * 2012-09-27 2013-01-16 同济大学 Synthetic method of JAK (janus kinase) inhibitor Tofacitinib
CN103819474A (en) * 2013-11-04 2014-05-28 湖南华腾制药有限公司 Preparation method of tofacitinib
MX362290B (en) * 2013-12-09 2019-01-10 Unichem Lab Ltd An improved process for the preparation of (3r,4r)-(1-benzyl-4-me thylpiperidin-3-yl)-methylamine.
AU2016208906B2 (en) * 2015-01-20 2018-07-12 Wuxi Fortune Pharmaceutical Co., Ltd JAK inhibitor
CN105237463B (en) * 2015-10-09 2017-10-10 刘卫国 Preparation methods of one kind (3R, 4R) (base of 1 benzyl, 4 methyl piperidine 3) methylamine L bis- to toluoyltartrates
CN106146517B (en) * 2016-06-20 2018-08-28 山东大学 A kind of synthetic method of citric acid tropsch imatinib
CN107602569A (en) * 2017-10-23 2018-01-19 上海博悦生物科技有限公司 A kind of new pyrrole simultaneously [2,3 d] pyrimidine compound and its preparation method and use
CN114835631B (en) * 2021-02-01 2024-02-13 重庆恩联生物科技有限公司 Preparation method of cis-1-benzyl-4-methyl-3-methylamino-piperidine dihydrochloride

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020509B1 (en) * 1999-12-10 2005-06-30 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
ATE423120T1 (en) * 2000-06-26 2009-03-15 Pfizer Prod Inc PYRROLOÄ2,3-DÜPYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE ACTIVES
EP1689407A1 (en) * 2003-11-25 2006-08-16 Pfizer Products Inc. Method of treatment of atherosclerosis

Also Published As

Publication number Publication date
TW200823216A (en) 2008-06-01
WO2008029237A3 (en) 2008-05-15
JP2008069149A (en) 2008-03-27
WO2008029237A2 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
AR062658A1 (en) COMBINATION THERAPIES FOR REUMATOID ARTHRITIS
CO6160236A2 (en) QUINASE INHIBITOR
AR065033A1 (en) METHODS TO PREVENT AND TREAT NEURODEGENERATIVE DISORDERS
CL2013001136A1 (en) A phosphodiesterase 7 (pde7) inhibitory agent to be used in the treatment or reduction of the possibility of an addiction; and pharmaceutical composition, unit dosage form and pharmaceutical kit including phosphodiesterase 7 inhibitor (pde7) and an additional therapeutic agent.
CL2007003523A1 (en) COMPOUNDS DERIVED FROM HETEROCICLES REPLACED WITH MORFOLINA, INHIBITORS OF THE ACTIVITY OF PI3 QUINASA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; PHARMACEUTICAL KIT; AND ITS USE IN THE CANCER PROFILACTIC OR THERAPEUTIC TREATMENT
PA8778101A1 (en) METHODS AND COMPOSITIONS TO TREAT AND MONITOR THE TREATMENT OF DISORDERS ASSOCIATED WITH IL-13
MX2009012155A (en) A synergistic pharmaceutical combination for the treatment of cancer.
CL2007003520A1 (en) COMPOUNDS DERIVED FROM HETEROCICLES REPLACED WITH MORFOLINA, INHIBITORS OF THE PI3 QUINASA ACTIVITY; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; PHARMACEUTICAL KIT; AND ITS USE FOR CANCER PROFILACTIC OR THERAPEUTIC TREATMENT.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MY150797A (en) Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer
PL1986669T3 (en) The use of Bifidobacterium longum for the prevention and treatment of inflammation
CL2011000916A1 (en) Use of a combination of an epoxy ketone peptide proteasome inhibitor or an acceptable pharmaceutical salt thereof, and one or more other therapeutic agents to treat cancer.
ECSP11011030A (en) METHOD FOR TREATMENT OR PREVENTION OF THROMBOSIS USING DABIGATRAN ETEXYLATE OR A SALT OF THE SAME WITH AN IMPROVED SAFETY PROFILE ON CONVENTIONAL WARFARINE THERAPY.
NI200900106A (en) INHIBITORS OF THE ACTIVITY OF THE AKT.
CR11510A (en) USE OF A GAMMA-SECRETASE INHIBITOR FOR CANCER TREATMENT
MY150697A (en) Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
AR093182A1 (en) METHOD TO TREAT OVERWEIGHT OR OBESITY
AR071003A1 (en) PHARMACO AGAINST LIVER CANCER
AR060019A1 (en) PHARMACEUTICAL COMPOSITION, PRODUCT AND TREATMENT METHOD FOR A COGNITIVE DISORDER AND USES OF AN ACETILCOLINESTERASE INHIBITOR AND A 5- HT6 ANTAGONIST IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A COGNITIVE DISORDER
MX2014003180A (en) Methods for treating hcv.
WO2007058990A3 (en) Therapy using cytokine inhibitors
WO2018102687A3 (en) Combination therapy for treating cancer
CL2008003201A1 (en) Pharmaceutical composition comprising 0.5 to 50 mg of gaboxadol or a pharmaceutically acceptable salt thereof, and one or more inhibitors of pat1 and / or one or more inhibitors of oat, wherein said composition provides an in vivo plasma profile with a tmax longer than 20 minutes, useful in sleep disorders treatments.
CL2011000806A1 (en) Use of dabigatran etexilate or a salt thereof to prepare a useful medication for the prevention of stroke in patients suffering from atrial fibrillation.
CL2009000803A1 (en) Use of a pegylated variant of igf-1 to treat, prevent a neuromuscular disorder; method for the treatment, prevention and / or delay of a neuromuscular disorder; composition comprising the modified igf-1 variant

Legal Events

Date Code Title Description
FB Suspension of granting procedure